arrow
V

Vallerie V. McLaughlin

university of michigan
H指数:78
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study

拉利尼帕格治疗肺动脉高压(ADVANCE OUTCOMES):一项随机、双盲、安慰剂对照的3期研究

2026-07-280
OAAI
Sotatercept Safety and Efficacy in Intermediate–Low Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR

sotatercept 在中低风险肺动脉高压中的安全性和有效性:PULSAR 和 STELLAR 的合并分析

Chest
IF8.6
2026-05-270
PRE
Characteristics, Treatment Patterns and Outcomes of Patients with Pulmonary Arterial Hypertension by Race and Ethnicity Using Real-World Data from the Combined OPUS/OrPHeUS Studies

肺动脉高压患者按种族和族裔划分的特征、治疗模式与结局:使用Combined OPUS/OrPHeUS研究中的真实世界数据

2025-11-190
OAAI
Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension

评估帕萨生帕戈口服制剂在肺动脉高压中的疗效:来自GRIPHON及其开放标签扩展研究的完整观察期关于生存、安全性和给药方案模式的见解

2025-11-140
PRE
Clinical validation of a machine-learned, point-of-care system to IDENTIFY pulmonary hypertension

机器学习、即时检测系统识别肺动脉高压的临床验证

2025-09-221
PRE
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis

sotatercept 用于诊断后第一年的肺动脉高压

2025-09-012
PRE
Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study

Seralutinib治疗成人肺动脉高压:TORREY开放标签扩展研究

2025-08-110
OA
Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity

接受塞来昔帕治疗的肺动脉高压患者特征:SPHERE登记研究按种族和族裔分析

2025-08-040
OAAI
Corrigendum to ‘‘Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)’’ [J Heart Lung Transplant 43 (2024) 272–283]

勘误:“接受西洛他唑治疗的真实世界肺动脉高压患者疾病特征、治疗及结局:来自SPHERE登记研究(SelexiPag: tHe usErs dRug rEgistry)”[J Heart Lung Transplant 43 (2024) 272–283]

2025-05-140
OAAI
Corrigendum to ‘‘Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials’’ [The Journal of Heart and Lung Transplantation, 44 (2025) 135–146]

更正:关于“在肺动脉高压合并心血管代谢共病患者中 riociguat 的安全性与有效性:来自干预性临床试验的数据”[《心肺移植杂志》,44(2025)135–146]

2025-04-090
OAAI
Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials

riociguat在肺动脉高压和心脏代谢合并症患者中的安全性和有效性: 来自干预性临床试验的数据

2025-02-011
PRE
Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study

REVEAL Lite 2风险状态的变化与肺动脉高压患者的长期预后相关: GRIPHON研究的事后分析

2024-12-010
PRE
Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial
2024-11-011
PRE
Sustained benefit with seralutinib treatment: Lessons from the open-label extension (OLE) of the TORREY study
2024-10-300
PRE